ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 819.1 USD | +0.93% |
|
+1.24% | +40.41% |
| 04:10pm | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
| 04:00pm | Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
811.5
USD
Average target price
850.8
USD
Spread / Average Target
+4.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.41% | 731B | |
| +31.34% | 586B | |
| -7.29% | 348B | |
| +16.81% | 319B | |
| +0.33% | 273B | |
| +13.47% | 235B | |
| -6.63% | 203B | |
| +7.49% | 202B | |
| +3.95% | 159B | |
| -2.83% | 158B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Argus Adjusts Price Target on Eli Lilly to $840 From $770
